2016

/Tag:2016

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $29.5 Million in payments from HTIT received to date JERUSALEM, October 6, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator [...]

2018-05-30T18:41:21+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, September 19, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place September 20-22, 2016 in Las Vegas. [...]

2018-05-30T18:41:22+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 7, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 18th Annual Global Investment Conference, taking place [...]

2018-05-30T18:41:22+00:00 Categories: 新闻通稿|Tags: |

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

JERUSALEM, July 28, 2016 /PRNewswire/ -- Statistically Significant Results Across Key Glycemic Endpoints  Conference Call Today at 11:00 AM ET  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, today reported additional data from the recently concluded Phase IIb trial of [...]

2018-05-30T18:41:22+00:00 Categories: 新闻通稿|Tags: |

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

JERUSALEM, July 26, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director. "We are very pleased to welcome Dr. [...]

2018-05-30T18:41:23+00:00 Categories: 新闻通稿|Tags: |

Oramed Announces $6.5 Million Milestone Payment from HTIT

Payment comes in wake of positive topline phase IIB results JERUSALEM, June 21, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million [...]

2018-05-30T18:41:23+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

JERUSALEM, June 9, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be [...]

2018-05-30T18:41:24+00:00 Categories: 新闻通稿|Tags: |